{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=N-803&page=2", "query": { "intervention": "N-803", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=N-803&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-25T19:11:29.468Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03387111", "title": "QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Squamous Cell Carcinoma" ], "interventions": [ { "name": "Aldoxorubicin HCl", "type": "DRUG" }, { "name": "ETBX-011", "type": "BIOLOGICAL" }, { "name": "ETBX-021", "type": "BIOLOGICAL" }, { "name": "ETBX-051", "type": "BIOLOGICAL" }, { "name": "ETBX-061", "type": "BIOLOGICAL" }, { "name": "GI-4000", "type": "BIOLOGICAL" }, { "name": "GI-6207", "type": "BIOLOGICAL" }, { "name": "GI-6301", "type": "BIOLOGICAL" }, { "name": "haNK for infusion", "type": "BIOLOGICAL" }, { "name": "Avelumab", "type": "DRUG" }, { "name": "bevacizumab", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "nab-Paclitaxel", "type": "DRUG" }, { "name": "Necitumumab", "type": "DRUG" }, { "name": "SBRT", "type": "PROCEDURE" }, { "name": "N-803", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "PROCEDURE" ], "sponsor": "ImmunityBio, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2018-01-09", "completion_date": "2021-01-11", "has_results": true, "last_update_posted_date": "2024-08-05", "last_synced_at": "2026-09-25T19:11:29.468Z", "location_count": 1, "location_summary": "El Segundo, California", "locations": [ { "city": "El Segundo", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03387111" }, { "nct_id": "NCT06061809", "title": "N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Glioblastoma" ], "interventions": [ { "name": "Bevacizumab", "type": "DRUG" }, { "name": "PD-L1 t-haNK", "type": "DRUG" }, { "name": "N-803", "type": "DRUG" }, { "name": "Tumor Treating Fields (TTFields, 200 kHz)", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "ImmunityBio, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2024-08-07", "completion_date": "2030-12-31", "has_results": false, "last_update_posted_date": "2026-07-01", "last_synced_at": "2026-09-25T19:11:29.468Z", "location_count": 4, "location_summary": "El Segundo, California • Fullerton, California • Newport Beach, California + 1 more", "locations": [ { "city": "El Segundo", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT06061809" }, { "nct_id": "NCT03899480", "title": "Adoptive Transfer of Haploidentical NK Cells and N-803", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hiv", "HIV Infections", "Immune Deficiency" ], "interventions": [ { "name": "Haploidentical Natural Killer (NK) Cells", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 9, "start_date": "2019-05-01", "completion_date": "2021-04-01", "has_results": false, "last_update_posted_date": "2021-04-23", "last_synced_at": "2026-09-25T19:11:29.468Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT03899480" }, { "nct_id": "NCT07108036", "title": "A Study to Assess Anktiva in Patients With Long Covid-19.", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Long COVID" ], "interventions": [ { "name": "N-803 (IL-15 Superagonist)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ImmunityBio, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 20, "start_date": "2025-11-14", "completion_date": "2026-10", "has_results": false, "last_update_posted_date": "2026-05-11", "last_synced_at": "2026-09-25T19:11:29.468Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07108036" }, { "nct_id": "NCT02099539", "title": "QUILT-3.005: A Study of N-803 in Patients With Relapsed or Refractory Multiple Myeloma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Relapsed or Refractory Multiple Myeloma" ], "interventions": [ { "name": "N-803", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Altor BioScience", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2014-10-06", "completion_date": "2018-06-19", "has_results": true, "last_update_posted_date": "2024-09-26", "last_synced_at": "2026-09-25T19:11:29.468Z", "location_count": 4, "location_summary": "Minneapolis, Minnesota • St Louis, Missouri • Buffalo, New York + 1 more", "locations": [ { "city": "Minneapolis", "state": "Minnesota" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Buffalo", "state": "New York" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02099539" }, { "nct_id": "NCT06161545", "title": "Pembrolizumab + N-803 Alone or in Combination With PD-L1 t-haNK Cells for Resectable Head and Neck Squamous Cell Carcinoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Stage II Squamous Cell Carcinoma of the Head and Neck", "Stage III Squamous Cell Carcinoma of the Head and Neck", "Stage IV Squamous Cell Carcinoma of the Head and Neck" ], "interventions": [ { "name": "PD-L1 t-haNK cells", "type": "BIOLOGICAL" }, { "name": "pembrolizumab", "type": "DRUG" }, { "name": "N-803", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 40, "start_date": "2025-09-24", "completion_date": "2028-12-01", "has_results": false, "last_update_posted_date": "2026-09-18", "last_synced_at": "2026-09-25T19:11:29.468Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT06161545" }, { "nct_id": "NCT05096663", "title": "Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Advanced Lung Non-Small Cell Carcinoma", "Recurrent Lung Non-Small Cell Carcinoma", "Stage III Lung Cancer AJCC v8", "Stage IIIA Lung Cancer AJCC v8", "Stage IIIB Lung Cancer AJCC v8", "Stage IIIC Lung Cancer AJCC v8", "Stage IV Lung Cancer AJCC v8", "Stage IVA Lung Cancer AJCC v8", "Stage IVB Lung Cancer AJCC v8" ], "interventions": [ { "name": "Cobalamin", "type": "DIETARY_SUPPLEMENT" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Folic Acid", "type": "DIETARY_SUPPLEMENT" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Nogapendekin Alfa", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Ramucirumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DIETARY_SUPPLEMENT", "DRUG", "BIOLOGICAL" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 82, "start_date": "2022-03-15", "completion_date": "2027-12-01", "has_results": false, "last_update_posted_date": "2026-05-18", "last_synced_at": "2026-09-25T19:11:29.468Z", "location_count": 350, "location_summary": "Birmingham, Alabama • Goodyear, Arizona • Little Rock, Arkansas + 280 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Goodyear", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "Arroyo Grande", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05096663" }, { "nct_id": "NCT04898543", "title": "QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Solid Tumor" ], "interventions": [ { "name": "M-CENK, Suspension for Infusion, Cryopreserved (M-CENK) (Cohort 2 part B)", "type": "BIOLOGICAL" }, { "name": "N-803 (Cohort 2 part B)", "type": "BIOLOGICAL" }, { "name": "Apheresis collection of MNCs (part A)", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "ImmunityBio, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 50, "start_date": "2021-06-21", "completion_date": "2026-05-31", "has_results": false, "last_update_posted_date": "2025-12-11", "last_synced_at": "2026-09-25T19:11:29.468Z", "location_count": 2, "location_summary": "El Segundo, California • Newport Beach, California", "locations": [ { "city": "El Segundo", "state": "California" }, { "city": "Newport Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04898543" }, { "nct_id": "NCT06745908", "title": "Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "NSCLC Stage IV" ], "interventions": [ { "name": "N-803", "type": "DRUG" }, { "name": "Tislelizumab", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Prior failed checkpoint inhibitor", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ImmunityBio, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 507, "start_date": "2025-10-01", "completion_date": "2029-01", "has_results": false, "last_update_posted_date": "2026-07-27", "last_synced_at": "2026-09-25T19:11:29.468Z", "location_count": 19, "location_summary": "Springdale, Arkansas • El Segundo, California • Fountain Valley, California + 14 more", "locations": [ { "city": "Springdale", "state": "Arkansas" }, { "city": "El Segundo", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Glendale", "state": "California" }, { "city": "Los Alamitos", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06745908" }, { "nct_id": "NCT05642195", "title": "Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-Small Cell Lung Cancer", "Non-Small Cell Lung Carcinoma", "Carcinoma, Non-Small-Cell Lung", "Carcinomas" ], "interventions": [ { "name": "Montanide (Registered Trademark) ISA-51 VG Adjuvant", "type": "BIOLOGICAL" }, { "name": "H1299 Cell Lysates", "type": "BIOLOGICAL" }, { "name": "N-803", "type": "DRUG" }, { "name": "Ventana PD-L1 (SP263 or SP142) assay", "type": "DEVICE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "DEVICE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 30, "start_date": "2026-09-30", "completion_date": "2035-12-30", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-09-25T19:11:29.468Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT05642195" } ] }